CLYM Climb Bio, Inc.

NASDAQ
$8.87

Climb Bio, Inc. (CLYM) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share.

Climb Bio Beat Consensus Estimates
Thursday, November 5, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.22)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Climb Bio, Inc.

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.